# Study Comparing Bioequivalence of Two New Formulations of Premarin/MPA With Premarin/MPA Reference Formulation.

> **NCT00381251** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer**

## Conditions studied

- Postmenopausal Osteoporosis
- Postmenopause

## Interventions

- **DRUG:** Formulations A and B of Premarin/MPA 0.45 mg/0.5 mg and PREMPRO0.45 mg/0.5 mg

## Key facts

- **NCT ID:** NCT00381251
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** —
- **Final completion:** 2007-01
- **Target enrollment:** — (—)
- **Last updated:** 2007-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00381251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00381251, "Study Comparing Bioequivalence of Two New Formulations of Premarin/MPA With Premarin/MPA Reference Formulation.". Retrieved via MORVS 2026-10-28 from https://api.morvs.ai/clinical/NCT00381251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*